International trends in hepatocellular carcinoma incidence, 1978–2012

Petrick, Jessica L.; Florio, Andrea A.; Znaor, Ariana; Ruggieri, David; Laversanne, Mathieu; Álvarez, Christian S.; Ferlay, Jacques; Valery, Patricia C.; Bray, Freddie; McGlynn, Katherine A.

doi:10.1002/ijc.32723

Cited by 410 publications

(330 citation statements)

References 46 publications

Supporting

Mentioning

280

Contrasting

Unclassified

Order By: Relevance

“…The decreasing rate of HCV-related HCC was reported in Japan and Italy due to specific antiviral therapy, including direct acting antiviral agents. The increasing rates of cryptogenic HCC were observed in US, Western countries and some Asian countries possibly due to the emergence of metabolic syndrome and non-alocholic steatohepatitis (NASH) 34 . These results are mostly consistent with our single center study in Taiwan.…”

Section: Discussionmentioning

confidence: 99%

Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma

Liu

Hsu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Hepatocellular carcinoma (Hcc) is the fourth leading cause of cancer-related death worldwide, but its current status is unclear. We aimed to investigate the evolution of etiology, presentation, management and prognostic tool in HCC over the past 12 years. A total of 3349 newly diagnosed HCC patients were enrolled and retrospectively analyzed. the comparison of survival was performed by the Kaplan-Meier method with the log-rank test. Hepatitis B and c virus infection in Hcc were continuously declining over the three time periods (-2015; p < 0.001). At diagnosis, single tumor detection rate increased to 73% (p < 0.001), whereas vascular invasion gradually decreased to 20% in 2012-2015 (p < 0.001). Early stage HCC gradually increased from 2004-2007 to 2012-2015 (p < 0.001). The probability of patients receiving curative treatment and long-term survival increased from 2004-2007 to 2012-2015 (p < 0.001). The Cancer of Liver Italian Program (CLIP) and Taipei integrated Scoring (tiS) system were two more accurate staging systems among all. in conclusion, the clinical presentations of HCC have significantly changed over the past 12 years. Hepatitis B and C virusassociated Hcc became less common, and more patients were diagnosed at early cancer stage. patient survival increased due to early cancer detection that results in increased probability to undergo curative therapies.Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth leading cause of cancer-associated mortality in 2018 globally 1 . The incidence of HCC is high in East Asia with male prediomance 2-4 . Also, HCC is the second most common reason for cancer-related mortality in Taiwan 5 , an endemic area for hepatitis B virus (HBV).HBV infection in Taiwan in mainly due to perinatal mother-to-infant transmission of the virus. The carrier rate of hepatitis B surface antigen (HBsAg) in general population was as high as 15-20% 6 . Prospective cohort and meta-analyses studies showed a 10-to 100-fold increase in the risk of HCC development among subjects chronically infected with HBV 2,7 . In Taiwan, the vaccination program against HBV was initiated in July 1984, and has reduced the incidence of HCC in children and adolescent successfully 8,9 . In addition to HBsAg, positive serum HBV e antigen and HBV DNA level were also associated with increased cancer risk 10 . Cumulative evidence showed that antiviral therapy might suppress HBV replication and lead to reduced risk of HCC formation [11][12][13] . HCV infection is another risk factor for HCC. The risk for HCC development in patients with serologically confirmed HCV infection was estimated to be 17-fold 2 . Notably, in recent years, nonalcoholic fatty liver disease (NAFLD), which is often associated with obesity and diabetes mellitus, emerged as potentially new risk factor for HCC 3,14,15 .For patients with early stage HCC, surgical resection, liver transplantation or local ablation therapy are usually indicated, with 5-year survival rate up to 75% 14,16 . Transarterial chemoembolization i...

show abstract

Section: Discussionmentioning

confidence: 99%

Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma

Liu

Hsu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Currently, the population seroprevalence of HBV or HCV continues to decline, which was possibly due to large-scale HBV vaccination in newborns and common anti-HCV treatment worldwide (14,15) , and may contribute to the future declining rates of liver cancer in traditionally high-incident areas including East Asia (2) . However, such gains in the control of liver cancer are at risk of being reversed by the rising rates of T2D, obesity and NAFLD, which were largely related to unhealthy diet (16,17) .…”

mentioning

confidence: 99%

Diet and liver cancer risk: a narrative review of epidemiological evidence

et al. 2020

View full text Add to dashboard Cite

“…Bo Yang 1,2 † , Yonghui Zhao 3 † , Lan Wang 4 , Yuanyuan Zhao 1,2 , Lai Wei 1,2 , Dong Chen 1,2 * and Zhishui Chen 1,2 *…”

Section: Identification Of Plod Family Genes As Novel Prognostic Biommentioning

confidence: 99%

Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma

et al. 2020

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies with rising incidence and persistently high mortality. Previous researches have demonstrated that some PLOD family members are associated with tumor progression and metastasis in most human cancers. However, the prognostic and biological roles of PLODs in HCC remain largely unknown. Methods: ONCOMINE, HPA, UALCAN, GEPIA, cBioPortal, GeneMANIA, NetworkAnalyst, Metascape, DAVID 6.8, and TIMER were used to determine the prognostic values and biological function of PLOD family members in HCC. Results: The mRNA and protein expression patterns of PLOD family members were noticeably upregulated in HCC compared to normal tissue. The high expression levels of PLOD1 and PLOD2 genes were significantly correlated with higher tumor grades in HCC patients. In addition, the high expression levels of PLOD1-3 were remarkably associated with poor overall survival in HCC patients, while high PLOD1 and PLOD3 expression were markedly associated with worse disease-free survival. In the coexpression gene analysis, 20 genes were primarily associated with the differentially expressed PLOD family members in HCC cases. Through functional enrichment analysis, the biological functions of PLODs in HCC were mainly involved in collagen fibril organization, lysine degradation, collagen biosynthesis, and modifying enzymes. Furthermore, the expression levels of PLOD1-3 were positively correlated with the activities of tumor-infiltrating immune cells, including macrophages, neutrophils, CD4+ T cells, and dendritic cells. Besides, the expression levels of PLOD2 and PLOD3 were positively correlated with the infiltrating levels of B cells. Conclusion: The findings of this study could provide novel insights into the identification of prognostic biomarkers for HCC patients.

show abstract

International trends in hepatocellular carcinoma incidence, 1978–2012

Cited by 410 publications

References 46 publications

Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma

Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma

Diet and liver cancer risk: a narrative review of epidemiological evidence

Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma

Contact Info

Product

Resources

About